-
![3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](/abs-image/US/2019/09/24/US10421731B2/abs.jpg.150x150.jpg)
公开(公告)号：US10421731B2
公开(公告)日：2019-09-24
申请号：US16218126
申请日：2018-12-12
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, Jr. , David S. Millan , Matthew W. Martin , Kenneth W. Bair
IPC: A61K31/5513 , C07D243/14 , C07D267/14 , C07D413/06 , C07D413/12 , C07D413/04 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D417/04 , C07D471/04 , C07D498/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10 , C07D267/12
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
![[6,6] Fused bicyclic HDAC8 inhibitors](/abs-image/US/2019/08/06/US10370343B2/abs.jpg.150x150.jpg)
公开(公告)号：US10370343B2
公开(公告)日：2019-08-06
申请号：US16003861
申请日：2018-06-08
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Jennifer R. Thomason , Mary-Margaret Zablocki , Bingsong Han , Nicholas Barczak , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, Jr. , Kenneth W. Bair
IPC: C07D265/36 , C07D413/12 , C07D413/06 , C07D401/04 , C07D279/16 , C07D491/107 , C07D413/10 , C07D471/04 , C07D417/06 , C07D513/04 , C07D487/04 , C07D265/34 , C07D279/14
Abstract: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2′, L, X, W, Y1, Y2, Y3, and Y4 are described herein.
-
![3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS](/abs-image/US/2019/04/18/US20190112282A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190112282A1
公开(公告)日：2019-04-18
申请号：US16218126
申请日：2018-12-12
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, JR. , David S. Millan , Matthew W. Martin , Kenneth W. Bair
IPC: C07D267/14 , C07D413/04 , C07D267/12 , C07D413/06 , C07D401/06 , C07D417/04 , C07D471/04 , C07D498/04 , C07D243/14 , C07D291/08 , C07D498/08 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D495/10 , C07D491/107 , C07D413/08 , C07D493/08 , C07D413/12
CPC classification number: C07D267/14 , C07D243/14 , C07D267/12 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/12 , C07D413/14 , C07D417/04 , C07D471/04 , C07D491/107 , C07D493/08 , C07D495/10 , C07D498/04 , C07D498/08
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
![3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](/abs-image/US/2019/02/26/US10214501B2/abs.jpg.150x150.jpg)
公开(公告)号：US10214501B2
公开(公告)日：2019-02-26
申请号：US15013820
申请日：2016-02-02
Applicant: Forma Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, Jr. , David S. Millan , Matthew W. Martin , Kenneth W. Bair
IPC: A61K31/553 , C07D267/14 , C07D413/06 , C07D413/12 , C07D413/04 , C07D243/14 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D417/04 , C07D471/04 , C07D498/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10 , C07D267/12
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
![3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS](/abs-image/US/2019/01/17/US20190016692A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190016692A1
公开(公告)日：2019-01-17
申请号：US16133918
申请日：2018-09-18
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, JR. , David S. Millan , Matthew W. Martin
IPC: C07D267/14 , C07D413/04 , C07D267/12 , C07D413/06 , C07D401/06 , C07D417/04 , C07D471/04 , C07D498/04 , C07D243/14 , C07D291/08 , C07D498/08 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D495/10 , C07D491/107 , C07D413/08 , C07D493/08 , C07D413/12
Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
Patent Agency Ranking
![[6,6] fused bicyclic HDAC8 inhibitors](/abs-image/US/2018/07/24/US10029995B2/abs.jpg.150x150.jpg)
公开(公告)号：US10029995B2
公开(公告)日：2018-07-24
申请号：US15255817
申请日：2016-09-02
Applicant: Forma Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Jennifer R. Thomason , Mary-Margaret Zablocki , Bingsong Han , Nicholas Barczak , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia , Kenneth W. Bair
IPC: C07D265/36 , C07D413/12 , C07D413/06 , C07D401/04 , C07D279/16 , C07D491/107 , C07D413/10 , C07D471/04 , C07D417/06 , C07D513/04 , C07D487/04 , C07D265/34 , C07D279/14
Abstract: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2′, L, X, W, Y1, Y2, Y3, and Y4 are described herein.
-
![3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS](/abs-image/US/2016/08/04/US20160222028A1/abs.jpg.150x150.jpg)
27.发明申请3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 审中-公开3-ALKYL-4-AMIDO-BICYCLIC [4,5,0]氢氧化物作为HDAC抑制剂公开(公告)号：US20160222028A1
公开(公告)日：2016-08-04
申请号：US15013814
申请日：2016-02-02
Applicant: Forma Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Heather Davis , Aleksandra Rudnitskaya , David Lancia, JR. , Kenneth W. Bair , David S. Millan , Matthew W. Martin
IPC: C07D498/04 , C07D267/14 , C07D493/08 , C07D243/14 , C07D495/10 , C07D413/08 , C07D413/14 , C07D413/06 , C07D491/107
CPC classification number: C07D267/14 , C07D243/14 , C07D267/12 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/12 , C07D413/14 , C07D417/04 , C07D471/04 , C07D491/107 , C07D493/08 , C07D495/10 , C07D498/04 , C07D498/08
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
Abstract translation: 本公开涉及可用于治疗与HDAC相关的疾病或病症的锌依赖性组蛋白脱乙酰酶（HDAC）的抑制剂，例如具有式I的HDAC6：其中R，L，X 1，X 2，X 3，X 4， Y1，Y2，Y3和Y4。
-
公开(公告)号：US20200331847A1
公开(公告)日：2020-10-22
申请号：US16689252
申请日：2019-11-20
Applicant: FORMA Therapeutics, Inc.
Inventor： Kenneth W. Bair , Nicholas Barczak , Bingsong Han , David R. Lancia, JR. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Mary-Margaret Zablocki , Xiaozhang Zheng
IPC: C07C259/06 , A61K31/185 , C07D221/20 , A61K31/438 , A61K31/277 , C07D209/44 , A61K31/4035 , C07D295/155 , A61K31/451 , C07D471/10 , A61K31/435 , C07D487/10 , A61K31/407 , C07D495/10 , A61K31/397 , C07D235/14 , A61K31/4184 , C07D233/68 , A61K31/417 , C07D213/56 , A61K31/44 , C07D241/08 , A61K31/495 , C07D417/04 , A61K31/4439 , A61K31/5377 , C07D471/04 , C07D401/14 , C07D213/75 , C07D213/81 , C07D215/12 , C07D317/68 , C07D231/14 , C07D231/18 , C07D233/36 , C07D233/38 , C07D333/70 , C07D401/04 , C07D401/12 , C07D235/30 , C07D239/20 , C07D239/22 , C07D405/12 , C07D409/04 , C07D409/12 , C07D241/12 , C07D417/12 , C07D249/18 , C07D257/04 , C07D261/18 , C07D487/04 , C07D487/08 , C07D491/10 , C07D207/10 , C07D493/08 , C07D207/267 , C07D498/04 , C07D209/08 , C07D277/56 , C07D209/42 , C07D209/46 , C07D513/10 , C07D211/16 , C07D211/58 , C07D295/192 , C07D213/65 , C07D307/68
Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
-
![3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS](/abs-image/US/2020/01/02/US20200002298A1/abs.jpg.150x150.jpg)
公开(公告)号：US20200002298A1
公开(公告)日：2020-01-02
申请号：US16567007
申请日：2019-09-11
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Heather Davis , Aleksandra Rudnitskaya , David R. Lancia, JR. , Kenneth W. Bair , David S. Millan , Matthew W. Martin
IPC: C07D267/14 , C07D413/06 , C07D413/12 , C07D413/04 , C07D267/12 , C07D243/14 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D417/04 , C07D471/04 , C07D498/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
![3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](/abs-image/US/2019/11/19/US10479772B2/abs.jpg.150x150.jpg)
公开(公告)号：US10479772B2
公开(公告)日：2019-11-19
申请号：US16220035
申请日：2018-12-14
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, Jr. , David S. Millan , Matthew W. Martin
IPC: A61K31/553 , C07D498/04 , C07D267/14 , C07D413/06 , C07D413/12 , C07D413/04 , C07D243/14 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D417/04 , C07D471/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10 , C07D267/12
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
-
-
-
-
-
-
-
-
Search Results
62
records
(took 0.046 seconds)
